Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expression of Nrf2

Adagrasib (MRTX849), an approved and promising KRAS G12C inhibitor, has shown the promising results for treating patients with advanced non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) harboring KRAS-activating mutations. However, emergence of the acquired resistance limits its long-ter...

Full description

Bibliographic Details

Published in:	Pharmacological Research
Main Authors:	Zhuangzhuang Jiang, Shuqing Ye, Yingwei Wu, Chen Zhou, Feng Cao, Ninghua Tan
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Subjects:	Colorectal cancer Natural cyclopeptide RA-V Oxidative and ER stress DNA damage MRTX849 resistance Nrf2/GLS1 axis
Online Access:	http://www.sciencedirect.com/science/article/pii/S104366182400197X